-

Blackstone Real Estate Completes Acquisition of Premier Lab Office Portfolio from Brookfield Fund

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) today announced that Blackstone Property Partners Life Sciences (“BPP Life Sciences”) has completed its previously announced acquisition of a best‐in‐class, 2.3 million square foot portfolio of lab office buildings from a Brookfield Asset Management real estate fund for $3.4 billion. BPP Life Sciences is Blackstone Real Estate’s long-term, perpetual capital, core+ return life sciences strategy. BPP Life Sciences owns BioMed Realty, Blackstone’s life science real estate portfolio company.

Concurrent with close, Blackstone executed upon the sale of two life sciences assets affiliated with Johns Hopkins Medicine to Ventas, Inc. Pro forma for the sale, 97% of the portfolio is concentrated in Cambridge, Massachusetts. Two thirds of BioMed Realty’s platform, which has an enterprise value of approximately $20 billion, is concentrated in the Boston/Cambridge market, one of the fastest growing lab office submarkets in the country due to its adjacency to world-leading academic institutions and the largest cluster of pharmaceutical companies in the U.S.

Deutsche Bank Securities Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities LLC served as financial advisors to Blackstone, and Simpson Thacher & Bartlett LLP served as legal advisor. Eastdil Secured served as lead financial advisor to Brookfield, and Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor. Citigroup Global Markets Inc. also provided financial advisory services to Brookfield in connection with the transaction.

The transaction was announced on December 14, 2020.

About Blackstone Real Estate

Blackstone is a global leader in real estate investing. Blackstone’s real estate business was founded in 1991 and has $187 billion of investor capital under management. Blackstone is one of the largest property owners in the world, owning and operating assets across every major geography and sector, including logistics, multifamily and single-family housing, office, hospitality and retail. Our opportunistic funds seek to acquire undermanaged, well-located assets across the world. Blackstone’s Core+ strategy invests in substantially stabilized real estate globally through regional open-ended funds focused on high-quality assets and Blackstone Real Estate Income Trust, Inc. (BREIT), a non-listed REIT that invests in U.S. income-generating assets. Blackstone Real Estate also operates one of the leading global real estate debt businesses, providing comprehensive financing solutions across the capital structure and risk spectrum, including management of Blackstone Mortgage Trust (NYSE: BXMT).

Contacts

Ilana Mouritzen
Ilana.Mouritzen@Blackstone.com
Tel: (212) 583-5776

Blackstone

NYSE:BX

Release Versions

Contacts

Ilana Mouritzen
Ilana.Mouritzen@Blackstone.com
Tel: (212) 583-5776

More News From Blackstone

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom